Kentucky Department for Public Health announces COVID-19 vaccine distribution draft plan

Pfizer won't seek Covid-19 vaccine approval before mid-November

Besides, it expects to have data on the drug's safety by the third week of November, as per the report. As countries worldwide work to establish guidelines about prioritizing who gets the vaccine and when, healthcare officials said that the most vulnerable groups and those at the highest risk of getting sick from COVID-19 should be first in line.

The US agency, which is rising the vaccine along with Germany's BioNTech SE, has mentioned it'd perceive on the finish of the month whether or not its merchandise was highly effective.

"So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the USA soon after the safety milestone is achieved in the third week of November", Mr. Bourla wrote in an open letter. "All data contained in our U.S. application will be reviewed not only by the scientists of the FDA, but also by an external panel of independent experts in a public meeting called by the agency ".

Inactivated "classic" vaccines use a virus germ that has been killed while others use a weakened or "attenuated" strain that is virulent enough to provoke antibodies but not to cause disease. "As supplies of the vaccine rise, all Kentuckians are expected to have access", he said, adding that distributing the vaccine to as many as 4.4 million residents will likely take a year or more to complete. The company itself confirmed on its website that it had the aUS Food and Drug Administration (FDA) approval to enroll children 12 and under in your essay.

Pfizer and BioNTech's vaccine candidate, BNT162b2, is now being evaluated in a global Phase 3 study ongoing at more than 120 clinical sites worldwide including the United States, Brazil, South Africa and Argentina.

This comes at a time when COVID-19 cases in the USA are climbing slightly, but the coronavirus deaths are relatively level this month.

Two vaccinations by the end of the year?

Pfizer and Moderna, both funded by the United States government, launched the third phase of their clinical trials in late July and both are producing their doses simultaneously.

The company said it hopes to move ahead with the vaccine after safety data is available in the third week of November, immediately lifting the company's shares two percent in the US.

Fears of delays were raised after trials for two rival vaccines were put on hold in the United States in recent weeks. The current front-runners are Pfizer and Moderna Inc.

Recent cases in which recovered COVID patients were infected a second time with a new strain also raise the question of how long vaccines might last.

In July, the U.S. Department of Health and Human Services and the Department of Defense (DoD) announced an agreement with Pfizer for an initial order of 100 million doses of a coronavirus vaccine for the price of $1.95 billion, following EUA or licensure.

Related:

Comments


Other news